Literature DB >> 22670908

Confronting multidrug-resistant tuberculosis.

Richard E Chaisson, Eric L Nuermberger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22670908     DOI： 10.1056/NEJMe1204478

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  Discovery of novel drug targets and their functions using phenotypic screening of natural products.

Authors:  Junghwa Chang; Ho Jeong Kwon
Journal:  J Ind Microbiol Biotechnol       Date:  2015-09-12       Impact factor: 3.346

2.  Multidrug-resistant tuberculosis.

Authors:  Lia D'Ambrosio; Rosella Centis; Giovanni B Migliori
Journal:  N Engl J Med       Date:  2012-11-29       Impact factor: 91.245

Review 3.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

Review 4.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

5.  Improving health services for African migrants in China: A health diplomacy perspective.

Authors:  Megan M McLaughlin; Margaret C Lee; Brian J Hall; Marc Bulterys; Li Ling; Joseph D Tucker
Journal:  Glob Public Health       Date:  2014-05-07

Review 6.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

7.  Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

Authors:  Kevin Pethe; Pablo Bifani; Jichan Jang; Sunhee Kang; Seijin Park; Sujin Ahn; Jan Jiricek; Juyoung Jung; Hee Kyoung Jeon; Jonathan Cechetto; Thierry Christophe; Honggun Lee; Marie Kempf; Mary Jackson; Anne J Lenaerts; Ha Pham; Victoria Jones; Min Jung Seo; Young Mi Kim; Mooyoung Seo; Jeong Jea Seo; Dongsik Park; Yoonae Ko; Inhee Choi; Ryangyeo Kim; Se Yeon Kim; SeungBin Lim; Seung-Ae Yim; Jiyoun Nam; Hwankyu Kang; Haejin Kwon; Chun-Taek Oh; Yoojin Cho; Yunhee Jang; Junghwan Kim; Adeline Chua; Bee Huat Tan; Mahesh B Nanjundappa; Srinivasa P S Rao; Whitney S Barnes; René Wintjens; John R Walker; Sylvie Alonso; Saeyeon Lee; Jungjun Kim; Soohyun Oh; Taegwon Oh; Ulf Nehrbass; Sung-Jun Han; Zaesung No; Jinhwa Lee; Priscille Brodin; Sang-Nae Cho; Kiyean Nam; Jaeseung Kim
Journal:  Nat Med       Date:  2013-08-04       Impact factor: 53.440

8.  Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis.

Authors:  Chao Gao; Cuiting Peng; Yaojie Shi; Xinyu You; Kai Ran; Lu Xiong; Ting-Hong Ye; Lidan Zhang; Ningyu Wang; Yongxia Zhu; Kun Liu; Weiqiong Zuo; Luoting Yu; Yuquan Wei
Journal:  Sci Rep       Date:  2016-07-13       Impact factor: 4.379

Review 9.  Diagnostic accuracy of Xpert MTB/RIF for tuberculosis detection in different regions with different endemic burden: A systematic review and meta-analysis.

Authors:  Shiying Li; Bin Liu; Mingli Peng; Min Chen; Wenwei Yin; Hui Tang; Yuxuan Luo; Peng Hu; Hong Ren
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

10.  Getting health services to three million people with TB.

Authors:  Héctor Pérez
Journal:  J Int AIDS Soc       Date:  2014-03-24       Impact factor: 5.396
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.